Suchergebnisse - "Yoshihiro, Tomoyasu"

PubPharm (26)

1

Survival outcomes including salvage therapy of adult head and neck para-meningeal rhabdomyosarcoma : a multicenter retrospective study from Japan

enthalten in: BMC cancer | 2023

von Tsuchihashi, K. | Ito, M. | Arita, S. | +34

2

Survival outcomes including salvage therapy of adult head and neck para-meningeal rhabdomyosarcoma: a multicenter retrospective study from Japan

enthalten in: BMC cancer | 2023

von Tsuchihashi, K. | Ito, M. | Arita, S. | +34

3

Adult head and neck para-meningeal rhabdomyosarcoma: survival outcomes including salvage therapy

enthalten in: ResearchSquare.com | 2023

von Tsuchihashi, K. | Ito, M. | Arita, S. | +31

4

Inhibition of insulin-like growth factor-1 receptor enhances eribulin-induced DNA damage in colorectal cancer

enthalten in: Cancer science | 2022

von Yoshihiro, T. | Ariyama, H. | Yamaguchi, K. | +7

5

Potential therapeutic targets discovery by transcriptome analysis of an in vitro human gastric signet ring carcinoma model

enthalten in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association | 2022

von Yamaguchi, K. | Yoshihiro, T. | Ariyama, H. | +25

6

Potential therapeutic targets discovery by transcriptome analysis of an in vitro human gastric signet ring carcinoma model

enthalten in: Gastric cancer | 2022

von Yamaguchi, K. | Yoshihiro, T. | Ariyama, H. | +25

7

Potential therapeutic targets discovery by transcriptome analysis of an in vitro human gastric signet ring carcinoma model

enthalten in: Gastric cancer | 2022

von Yamaguchi, K. | Yoshihiro, T. | Ariyama, H. | +25

8

ANTICANCER ACTIVITY ENHANCER AND ANTICANCER DRUG

enthalten in: Europäisches Patentamt | 2022

von ARIYAMA HIROSHI | YOSHIHIRO TOMOYASU | BABA HIDEJI | +1

9

Inhibition of insulin‐like growth factor‐1 receptor enhances eribulin‐induced DNA damage in colorectal cancer

enthalten in: Cancer Science | 2022

von Yoshihiro, T. | Ariyama, H. | Yamaguchi, K. | +7

10

Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicin

enthalten in: Scientific reports | 2020

von Tsuchihashi, K. | Kusaba, H. | Yoshihiro, T. | +18